Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
SHR
Neuro
Krebs
Kardio
Stoffw
Microb
Lipid
Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo
- Abstract
- The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.
The extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).
The prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:
*Further development of thiomers for oral and topical (depot)delivery of active substances
*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs
*Development of targeted imaging for cancer using MRI
*Stem cell tracking in vivo
*Atherosclerotic plaque detection
*Chronic nanotoxicity
- Lokale Teilprojektleitung:
- Strunk Dirk
- Laufzeit:
- 01.03.2009-28.02.2012
- Subprogramm
- Nano-Health
- Art der Forschung
- Experimentelle Entwicklung
- Mitarbeiter*innen
- Strunk, Dirk, Projektleiter*in
- Reinisch, Andreas, Projektmitarbeiter*in
- Farrell, Monica, Projektmitarbeiter*in
- Ortner, Anna, Projektmitarbeiter*in
- Beteiligte MUG-Organisationseinheiten
- Klinische Abteilung für Hämatologie